Citations

Showing 10 of 108081 citations.

A Case of Oral-Vancomycin-Induced Rash in a Patient with Acute Kidney Injury
Cardozo, Milena , Parmar, Angadbir S., Prada, Libardo Rueda , Shweta, Fnu , Rueda Prada, Libardo , Shweta, Fnu , Cardozo, Milena

Mayo Clinic

Infectious Disease Reports | March 30, 2023 | Volume: 15 | Issue: 2 | Pages: 180-187

10.3390/idr15020019 | PMID 37102979 Get It

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infections. Its incidence has increased during the last decade in the community among individuals with no previous risk factors; however, morbidity and mortality are still considered high in elderly patients. Oral Vancomycin and Fidaxomicin are the first lines of treatment for CDI. The systemic bioavailability of oral Vancomycin is thought to be undetectable due to its poor absorption in the gastrointestinal tract; therefore, routine monitoring is not warranted. Only 12 case reports were found in the literature that described adverse reactions associated with oral Vancomycin and its related risk factors. We present a case of a 66-year-old gentleman with severe CDI and acute renal failure who was started on oral Vancomycin upon admission. On day five of treatment, he developed leukocytosis associated with neutrophilia, eosinophilia, and atypical lymphocytes, with no evidence of active infection. Three days later, he developed a pruritic maculopapular rash in more than 50% of his body surface area. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) was ruled out since the patient only had three inclusion criteria for this diagnosis. No clear inciting agent was found. Oral Vancomycin was stopped and supportive treatment was supplied for a presumed Vancomycin-induced allergic reaction. The patient had an excellent response, with complete resolution of the rash and leukocytosis in less than 48 h. By reporting this case, we want to raise awareness among clinicians to remember that, albeit rare, oral Vancomycin can be the cause of adverse drug reactions in patients with severe illnesses.
Deep Phenotype Characterization of Hypertensive Response to Exercise: Implications on Functional Capacity and Prognosis Across the Heart Failure Spectrum
Biase, Nicolò De , Punta, Lavinia Del, Balletti, Alessio , Armenia, Silvia, Buralli, Simona, Metra, Marco , Williams, Bryan , Metra, Marco , Pugliese, Nicola Riccardo , Mengozzi, Alessandro , Taddei, Stefano , Pagnesi, Matteo , Borlaug, Barry A. , Masi, Stefano

Mayo Clinic

European Journal of Heart Failure | March 30, 2023 | Volume: 25 | Issue: 4 | Pages: 497-509

10.1002/ejhf.2827 | PMID 36992634 Get It

Abstract Aims Limited evidence is available regarding the role of hypertensive response to exercise (HRE) in heart failure (HF). We evaluated the systolic blood pressure (SBP) to workload slope during exercise across the HF spectrum, investigating haemodynamic and prognostic correlates of HRE. Methods and results We prospectively enrolled 369 patients with HF Stage C (143 had preserved [HFpEF], and 226 reduced [HFrEF] ejection fraction), 201 subjects at risk of developing HF (HF Stages A–B), and 58 healthy controls. We performed a combined cardiopulmonary exercise stress echocardiography testing. We defined HRE as the highest sex-specific SBP/workload slope tertile in each HF stage. Median SBP/workload slope was 0.53 mmHg/W (interquartile range 0.36–0.72); the slope was 39% steeper in women than men (p < 0.0001). After adjusting for age and sex, SBP/workload slope in HFrEF (0.47, 0.30–0.63) was similar to controls (0.43, 0.35–0.57) but significantly lower than Stages A–B (0.61, 0.47–0.75) and HFpEF (0.63, 0.42–0.86). Patients with HRE showed significantly lower peak oxygen consumption and peripheral oxygen extraction. After a median follow-up of 16 months, HRE was independently associated with adverse outcomes (all-cause mortality and hospitalization for cardiovascular reasons: hazard ratio 2.05, 95% confidence interval 1.81–5.18), while rest and peak SBP were not. Kaplan–Meier analysis confirmed a worse survival probability in Stages A–B (p = 0.005) and HFpEF (p < 0.001), but not HFrEF. Conclusion A steeper SBP/workload slope is associated with impaired functional capacity across the HF spectrum and could be a more sensitive predictor of adverse events than absolute SBP values, mainly in patients in Stages A–B and HFpEF.
Global Longitudinal Strain Is Associated with Mortality in Patients with Multiple Myeloma
Cui, Zhu, Castagna, Francesco , Hanif, Waqas , Apple, Samuel J. , Zhang, Lili , Tauras, James M. , Braunschweig, Ira , Kaur, Gurbakhash , Janakiram, Murali , Díaz, Juan Carlos , Hoyos, Carolina , Marín, Jorge E. , García, Mario J. , Verma, Amit , Slipczuk, Leandro , Verma, Amit , Diaz, Juan C , Hoyos, Carolina , Marin, Jorge , Slipczuk, Leandro , Kaur, Gurbakhash , Janakiram, Murali , Wang, Yanhua , Fang, Yanan , Pellikka, Patricia A. , Romero, Jorge E. , Shah, Nishi

Mayo Clinic

Journal of Clinical Medicine | March 30, 2023 | Volume: 12 | Issue: 7 | Pages: 2595

10.3390/jcm12072595 | PMID 37048679 Get It

Patients with multiple myeloma (MM) are at a high risk for developing cardiovascular complications. Global longitudinal strain (GLS) can detect early functional impairment before structural abnormalities develop. It remains unknown if reduced GLS is associated with reduced survival in patients with MM. We conducted a retrospective cohort analysis of patients diagnosed with MM between 1 January 2000 and 31 December 2017 at our institution. Patients with a 2D transthoracic echocardiogram completed within 1 year of MM diagnosis, left ventricular ejection fraction (LVEF) greater than 40%, and no history of myocardial infarction prior to MM diagnosis were included. GLS was measured using an artificial-intelligence-powered software (EchoGo Core), with reduced GLS defined as an absolute value of <18%. The primary outcome of interest was overall survival since myeloma diagnosis. Our cohort included 242 patients with a median follow up of 4.28 years. Fifty-two (21.5%) patients had reduced average GLS. Patients with reduced GLS were more likely to have an IVSd ≥ 1.2cm, E/E’ > 9.6, LVEF/GLS > 4.1, higher LV mass index, and low-voltage ECG. A Total of 126 (52.1%) deaths occurred during follow-up. Overall survival was lower among patients with reduced GLS (adjusted HR: 1.81, CI: 1.07–3.05).
Rotating Gantries Provide Individualized Beam Arrangements for Charged Particle Therapy
Chinniah, Siven, Deisher, A., Herman, Michael , Johnson, J. , Mahajan, Anita , Foote, Robert L. , Foote, Robert

Mayo Clinic

Cancers | March 30, 2023 | Volume: 15 | Issue: 7 | Pages: 2044

10.3390/cancers15072044 | PMID 37046705 Get It

Purpose: This study evaluates beam angles used to generate highly individualized proton therapy treatment plans for patients eligible for carbon ion radiotherapy (CIRT). Methods and Materials: We retrospectively evaluated patients treated with pencil beam scanning intensity modulated proton therapy from 2015 to 2020 who had indications for CIRT. Patients were treated with a 190° rotating gantry with a robotic patient positioning system. Treatment plans were individualized to provide maximal prescription dose delivery to the tumor target volume while sparing organs at risk. The utilized beam angles were grouped, and anatomic sites with at least 10 different beam angles were sorted into histograms. Results: A total of 467 patients with 484 plans and 1196 unique beam angles were evaluated and characterized by anatomic treatment site and the number of beam angles utilized. The most common beam angles used were 0° and 180°. A wide range of beam angles were used in treating almost all anatomic sites. Only esophageal cancers had a predominantly unimodal grouping of beam angles. Pancreas cancers showed a modest grouping of beam angles. Conclusions: The wide distribution of beam angles used to treat CIRT-eligible patients suggests that a rotating gantry is optimal to provide highly individualized beam arrangements.
Editorial: A Tribute to Mediterranean Pioneers in Facial Plastic and Craniomaxillofacial Surgery
Hallak, Hana , Sharaf, Basel , Sharaf, Basel A, Sharaf, Basel A

Mayo Clinic

Journal of Craniofacial Surgery | March 30, 2023 | Volume: 34 | Issue: 3 | Pages: 1126-1128

10.1097/scs.0000000000009286 | PMID 36991545 Get It

Background: Physicians from the Mediterranean civilization were profoundly instrumental in the early development and contemporary advancement of the craniomaxillofacial field. These feats are scarcely studied or acclaimed. In this editorial, the authors explore the contributions of these major Mediterranean pioneers. Methods: A literature review on the subject was performed using PubMed, Scopus, Embase, and Mayo Clinic Libraries. Results: Mediterranean medicine has recognized and managed craniomaxillofacial pathologies from as early as the 10th century. The first inscriptions were authored by Abu Alkasem al-Zahrawi and Serefeddin Sabuncuoglu. Starting in the 15th century, Leonardo da Vinci shed light on anatomy and esthetics at a time where Gasparo Tagliacozzi spearheaded maxillofacial techniques. The field during the Renaissance was dominated by Hippocrates Asclepiades. Varaztad Kazanjian revolutionized the armamentarium necessitated by mass emergencies during the World War. In the 20th century, Paul Tessier redefined the limits of craniomaxillofacial treatment by using facial osteotomies and developing refined surgical instruments. Modern day Sam Hamra, Enrico Robotti, and Daniel Labbé continue to lead educational and innovative fronts of the field. Conclusions: This essay highlights some important historical contributions to the fields of craniomaxillofacial and facial plastic surgery by pioneer surgeons from around the Mediterranean.
CT Perfusion vs Noncontrast CT for Late Window Stroke Thrombectomy
Kobeissi, Hassan , Ghozy, Sherief , Bilgin, Cem , Tolba, Hatem , Amoukhteh, Melika , Kadirvel, Ramanathan , Brinjikji, Waleed , Heit, Jeremy J. , Kallmes, David F. , Adusumilli, Gautam , Heit, Jeremy J , Ghozy, Sherief , Kobeissi, Hassan , Rabinstein, Alejandro A.

Mayo Clinic

Neurology | March 29, 2023 | Volume: 100 | Issue: 22 | Pages: No page available

10.1212/wnl.0000000000207262 | PMID 36990720 Get It

Nonlinear Mixed Effects Modeling of Glucagon Kinetics in Healthy Subjects
Faggionato, Edoardo , LAURENTI, MARCELLO C. , Man, Chiara Dalla , Dalla Man, Chiara , Vella, Adrian

Mayo Clinic

IEEE Transactions on Biomedical Engineering | March 29, 2023 | Volume: 70 | Issue: 9 | Pages: 2733-2740

10.1109/tbme.2023.3262974 | PMID 37030857 Get It

Paper 24: Osteochondritis Dissecans of the Capitellum of the Elbow: A Comparison of Non-Operative and Surgical Outcomes at Long-Term Follow-up
Braig, Zachary, Uvodich, Mason E. , Till, Sara E., Reinholz, Anna K., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , O’Driscoll, Shawn W. , Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 29, 2023 | Volume: 11 | Issue: 3_suppl2 | Pages: No page available

10.1177/2325967123s00024 Get It

Objectives: Osteochondritis dissecans (OCD) of the humeral capitellum is an often painful condition that typically affects the adolescent athlete. There is little consensus on treatment and a scarcity of long-term outcomes data. The purpose of this study was to (1) report the long-term outcomes associated with both operative and non-operative management of capitellar OCD, (2) identify factors associated with failure of non-operative management, and (3) determine whether delay in surgery affects final outcomes. Methods: All patients diagnosed with OCD of the capitellum from 1995-2020 within a defined geographic cohort were included. Medical records, imaging studies, and operative reports were manually reviewed to record demographic data, treatment strategies, and outcomes. Surgical treatment was considered delayed if it occurred more than 6 months after symptom onset. Results: A total of 50 elbows with a mean follow-up of 9.4 years were included. Of these, 7 (14%) were treated non-operatively and never underwent surgery during follow-up, while 43 (86%) underwent surgical intervention: 27 had early surgery and 16 underwent delayed surgery after ≥ 6 months of non-operative treatment. When compared to non-operative management, surgical management resulted in superior MEPI scores (90 vs 83, p=0.05), decreased persistence of mechanical symptoms (9% vs 50%, p<0.01), and better elbow flexion (141° vs 131°, p=0.01) at long-term follow up. Older patients had a trend toward increased failure of non-operative management (p=0.06). The presence of an intra-articular loose body strongly predicted failure of non-operative management (p=0.01; OR 13). Plain radiography and MRI had poor sensitivities for identifying loose bodies (27% and 40%, respectively). Differences in outcomes following early versus delayed surgical management were not demonstrated. Conclusions: Patients with capitellar OCD initially treated nonoperatively failed nonoperative management 70% of the time. Elbows that did not undergo surgery had slightly increased symptoms and decreased functional outcomes compared to those treated surgically. In this cohort, the greatest predictors for failure of non-operative treatment were older age and presence of a loose body; however, an initial trial of non-operative treatment did not adversely impact the success of future surgery at long term follow-up. [Table: see text][Table: see text][Table: see text][Table: see text]
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma
Upshaw, Jenica , Nelson, Jason, Rodday, Angie Mae , Kumar, Anita J. , Klein, Andreas K. , Konstam, Marvin A. , Ky, Bonnie , Friedberg, Jonathan W. , Kent, David M. , Parsons, Susan K. , Ky, Bonnie , K Parsons, Susan , Kent, David M , Wong, John B. , Jaffe, Iris Zamir , Maurer, Matthew J.

Mayo Clinic

JAMA Cardiology | March 29, 2023 | Volume: 8 | Issue: 5 | Pages: 453

10.1001/jamacardio.2023.0303 | PMID 36988926 Get It

ImportanceAnthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.ObjectiveTo assess the prevalence of preexisting HF in older patients with DLBCL and its association with treatment patterns and outcomes.Design, Setting, and ParticipantsThis longitudinal cohort study used data from the Surveillance, Epidemiology, and End Results (SEER)–Medicare registry from 1999 to 2016. The SEER registry is a system of population-based cancer registries, capturing more than 25% of the US population. Linkage to Medicare offers additional information from billing claims. This study included individuals 65 years and older with newly diagnosed DLBCL from 2000 to 2015 with Medicare Part A or B continuously in the year prior to lymphoma diagnosis. Data were analyzed from September 2020 to December 2022.ExposuresPreexisting HF in the year prior to DLBCL diagnosis ascertained from billing codes required one of the following: (1) 1 primary inpatient discharge diagnosis, (2) 2 outpatient diagnoses, (3) 3 secondary inpatient discharge diagnoses, (4) 3 emergency department diagnoses, or (5) 2 secondary inpatient discharge diagnoses plus 1 outpatient diagnosis.Main Outcomes and MeasuresThe primary outcome was anthracycline-based treatment. The secondary outcomes were (1) cardioprotective medications and (2) cause-specific mortality. The associations between preexisting HF and cancer treatment were estimated using multivariable logistic regression. The associations between preexisting HF and cause-specific mortality were evaluated using cause-specific Cox proportional hazards models with adjustment for comorbidities and cancer treatment.ResultsOf 30 728 included patients with DLBCL, 15 474 (50.4%) were female, and the mean (SD) age was 77.8 (7.2) years. Preexisting HF at lymphoma diagnosis was present in 4266 patients (13.9%). Patients with preexisting HF were less likely to be treated with an anthracycline (odds ratio, 0.55; 95% CI, 0.49-0.61). Among patients with preexisting HF who received an anthracycline, dexrazoxane or liposomal doxorubicin were used in 78 of 1119 patients (7.0%). One-year lymphoma mortality was 41.8% (95% CI, 40.5-43.2) with preexisting HF and 29.6% (95% CI, 29.0%-30.1%) without preexisting HF. Preexisting HF was associated with higher lymphoma mortality in models adjusting for baseline and time-varying treatment factors (hazard ratio, 1.24; 95% CI, 1.18-1.31).Conclusions and RelevanceIn this study, preexisting HF in patients with newly diagnosed DLBCL was common and was associated with lower use of anthracyclines and lower use of any chemotherapy. Trials are needed for this high-risk population.
Hear Me Out: Mitigating Cisplatin-Induced Ototoxicity
Desai, Aakash , Das, Devika , Desai, Aakash P

Mayo Clinic

JCO Oncology Practice | March 29, 2023 | Volume: 19 | Issue: 5 | Pages: 284-285

10.1200/op.23.00120 | PMID 36989461 Get It